The Chief Medical Officer for England has called on NHS England to fund PrEP drugs aimed to decrease the risk of being infected with HIV. The med named Truvada can reduce the risk of being infected with HIV by up to 86% if taken daily, and has been endorsed by the World Health Organisation and Centers for Disease Control and Prevention for at-risk men who have sex with men (MSM).
England’s Chief Medical Officer Dame Sally Davies told the Financial Times: “Whatever one thinks about it morally or anything, I can tell you it is a cost-effective public health intervention, so I do believe our system should fund it. You save infections and therefore money, and it has been thoroughly checked. The issue is whether it should be funded, and I think you have to separate the cost-effectiveness from whatever you think as a person.” Health experts agree that however expensive the HIV-preventing drugs will be for British people belonging to the risk groups (in part MSM), it will be still cheaper than to treat those who are HIV+, especially considering the increasing rates of HIV in UK